Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adult Subjects With Moderate to Severe Hidradenitis Suppurativa

NCT04430855 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT04430855
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04430855 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adult Subjects With Moderate to Severe Hidradenitis Suppurativa
Lead sponsor
AbbVie
Phase
Phase 2
Overall status
Completed
Start date
July 14, 2020
Completion date
January 25, 2022
Enrollment
68 (actual)
Sites
26

Conditions

As the registry lists them; a condition with its own page is linked.

hidradenitis suppurativa (hs)